PWM
VRTX icon

Parkworth Wealth Management’s Vertex Pharmaceuticals VRTX Stock Holding History

Parkworth Wealth Management’s Portfolio VRTX Stock Details VRTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q2 		$1.78K Buy
4
+1
+33% +$461 ﹤0.01% 285
2025
Q1 		$1.45K Hold
3
– – ﹤0.01% 210
2024
Q4 		$1.21K Buy
+3
New +$1.39K ﹤0.01% 250

Other funds holding VRTX

Capital World Investors
Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Capital Research Global Investors
Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Jennison Associates
Jennison Associates New York $145B AUM 34.61% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

Parkworth Wealth Management's VRTX Position: Q2 2025 in Review

Parkworth Wealth Management increased its Vertex Pharmaceuticals (VRTX) stake by 33% in Q2 2025, buying an estimated $461 and bringing the position to 4 shares worth $1.78K. The position accounts for ﹤0.01% of the portfolio, ranked #285.

Parkworth Wealth Management first reported a position in VRTX in Q4 2024 and has held it in 3 quarters since. 1,559 funds tracked by Wall St. Rank hold VRTX as of Q2 2025.

  • Parkworth Wealth Management held 4 shares of Vertex Pharmaceuticals worth $1.78K as of Q2 2025.
  • Parkworth Wealth Management bought 1 Vertex Pharmaceuticals share in Q2 2025, an estimated $461.
  • Vertex Pharmaceuticals made up ﹤0.01% of Parkworth Wealth Management's portfolio in Q2 2025, its #285 holding.
  • Parkworth Wealth Management first reported a position in Vertex Pharmaceuticals in Q4 2024 and has held it in 3 quarters since.
  • 1,559 funds tracked by Wall St. Rank held Vertex Pharmaceuticals as of Q2 2025.

Based on Parkworth Wealth Management's 13F filing for Q2 2025, filed 13 Aug 2025.